Conversely, inhibitory measures targeting GRP94 have exhibited efficacy in restoring ER homeostasis and ameliorating pathological sequelae across diverse ailments, including cancer and immune‐mediated inflammation (Pugh et al. 2022). The gene discussed is HSP90B1; the disease is cancer.